The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
Interpreting PD-L1 Status Among Key Melanoma Topics at ASCO
June 25th 2015OncLive sat down with Jason J. Luke, MD, discusses the key areas in the treatment of melanoma discussed at the 2015 ASCO Annual Meeting included selecting appropriate immunotherapy regimens based on PD-L1 status and improving surgical practices.
Nationwide Precision Medicine Trial Coming to Sylvester Comprehensive Cancer Center
June 24th 2015Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine will be one of the sites offering the landmark precision medicine trial, NCI-MATCH – a trial that will open to patient enrollment in July.
UHealth Neurosurgeon Using New Technology to Remove Brain Tumors
June 24th 2015Ricardo J. Komotar, M.D., Director of Surgical Neuro-oncology at UHealth – University of Miami Health System, is the first neurosurgeon in Miami-Dade and Broward counties to remove a brain tumor using the NICO BrainPath system.
Panitumumab Improves OS Versus Supportive Care in Phase III mCRC Trial
June 19th 2015Patients with chemorefractory KRAS wild-type metastatic colorectal cancer had a statistically significant improvement in overall survival when treated with panitumumab (Vectibix) versus best supportive care, according to data released from a phase IlI study.
VCU Massey Cancer Center Joins OncLive's® Strategic Alliance Partnership Program
June 17th 2015OncLive® announced an addition to its vibrant Strategic Alliance Partnership program today as VCU Massey Cancer Center signed onto the program's mission to raise awareness of cancer treatment and research.
PEGPH20 Combination Doubles PFS in HA-High Pancreatic Cancer
June 16th 2015The addition of PEGPH20 to standard nab-paclitaxel and gemcitabine improved progression-free survival by 4.9 months compared with the two agents alone in untreated patients with advanced pancreatic cancer who expressed high-levels of hyaluronan.
Olanzapine Shown to Control CINV in Patients With Esophageal, Head and Neck Cancer
June 15th 2015Olanzapine (Zyprexa) demonstrated an improvement in antinausea effects in patients receiving concurrent highly emetogenic chemotherapy and radiation therapy for advanced stage head and neck and esophageal cancer when compared to fosaprepitant.
Panobinostat PFS Benefit Extended in PANORAMA-1 Subgroup Analysis
June 13th 2015The addition of panobinostat to bortezomib and dexamethasone improved progression-free survival by 7.8 months in a subgroup of 147 patients with multiple myeloma who had received at least 2 prior treatments, including bortezomib and an immunomodulatory agent.